These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

63 related items for PubMed ID: 16401924

  • 1. Serum amino-terminal propeptide of type 1 procollagen (P1NP) in prostate cancer: a potential predictor of bone metastases and prognosticator for disease progression and survival.
    Thurairaja R, Iles RK, Jefferson K, McFarlane JP, Persad RA.
    Urol Int; 2006; 76(1):67-71. PubMed ID: 16401924
    [Abstract] [Full Text] [Related]

  • 2. Procollagen type 1 amino-terminal propeptide: a marker for bone metastases in prostate carcinoma.
    Klepzig M, Jonas D, Oremek GM.
    Anticancer Res; 2009 Feb; 29(2):671-3. PubMed ID: 19331219
    [Abstract] [Full Text] [Related]

  • 3. Serum procollagen 1 amino-terminal propeptide (P1NP) in prostate cancer: pitfalls of its use as an early surrogate marker for bone metastasis.
    Moseshvili E, Joseph DJ, Spry NA, Cohen RJ, Abreu A, Kautto A, Denham JW.
    J Med Imaging Radiat Oncol; 2014 Aug; 58(4):497-502. PubMed ID: 24418365
    [Abstract] [Full Text] [Related]

  • 4. The value of serum carboxyterminal propeptide of type 1 procollagen in predicting bone metastases in prostate cancer.
    Nakashima J, Sumitomo M, Miyajima A, Jitsukawa S, Saito S, Tachibana M, Murai M.
    J Urol; 1997 May; 157(5):1736-9. PubMed ID: 9112516
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The amino-terminal propeptide (PINP) of type I collagen is a clinically valid indicator of bone turnover and extent of metastatic spread in osseous metastatic breast cancer.
    Pollmann D, Siepmann S, Geppert R, Wernecke KD, Possinger K, Lüftner D.
    Anticancer Res; 2007 May; 27(4A):1853-62. PubMed ID: 17649784
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Total procollagen type 1 amino-terminal propeptide (total P1NP) as a bone metastasis marker in gynecological carcinomas.
    Oremek G, Sauer-Eppel H, Klepzig M.
    Anticancer Res; 2007 May; 27(4A):1961-2. PubMed ID: 17649805
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Prognostic value of serum markers for prostate cancer.
    Stenman UH, Abrahamsson PA, Aus G, Lilja H, Bangma C, Hamdy FC, Boccon-Gibod L, Ekman P.
    Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Serum sclerostin levels in Paget's disease and prostate cancer with bone metastases with a wide range of bone turnover.
    Yavropoulou MP, van Lierop AH, Hamdy NA, Rizzoli R, Papapoulos SE.
    Bone; 2012 Jul; 51(1):153-7. PubMed ID: 22579776
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Measurements and clinical usefulness of carboxyterminal propeptide of type I collagen and cross-linked carboxyterminal telopeptide of type I collagen in patients with prostate cancer].
    Igawa T, Sakai H, Kanetake H, Saito Y.
    Hinyokika Kiyo; 1999 Apr; 45(4):235-9. PubMed ID: 10363141
    [Abstract] [Full Text] [Related]

  • 19. A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases.
    Lara PN, Stadler WM, Longmate J, Quinn DI, Wexler J, Van Loan M, Twardowski P, Gumerlock PH, Vogelzang NJ, Vokes EE, Lenz HJ, Doroshow JH, Gandara DR.
    Clin Cancer Res; 2006 Mar 01; 12(5):1556-63. PubMed ID: 16533781
    [Abstract] [Full Text] [Related]

  • 20. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover.
    van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE.
    J Bone Miner Res; 2011 Dec 01; 26(12):2804-11. PubMed ID: 21786318
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.